Skip to main content
. 2021 Sep 23;11:18936. doi: 10.1038/s41598-021-98410-0

Figure 1.

Figure 1

Schematic diagram of the workflow. First, we characterized the protein signatures of 49 cases in the discovery cohort, including 19 primary tumors (10 NAG and 9 AG), 20 metastatic tumors (10 Nmet and 10 M) and 10 benign controls (C). Next, we further validated our findings by the targeted re-examination of SWATH-MS maps using the independently collected cohort, including 29 primary PCa (19 NAG and 10 AG) and 28 metastatic tumors (M). C: benign control, NAG: non-aggressive PCa, AG: aggressive PCa, Nmet: metastasis without androgen deprivation therapy; M: metastasis with androgen deprivation therapy.